@Screenlover Thought id at least get an apology.
Fact check Mr Magoo 3 meetings were held.
In April 2025, PainChek advised investors it was required to give ‘additional information for clarification’. (1.)Such a meeting was held. (2.) & (3.)Two further meetings were held in May and June. Despite the company saying it was,’ A positive two-way conversation providing feedback and clarity for both parties’, it was,’compiling additional information collected from the completed clinical study that addresses the FDA feedback and aligns with the agreed actions concluded during the meeting’.prior to the end of June, and it expects clearance within 75 days which would be mid to late September. Despite the company telling investors it expected this, and it taken steps like recruiting a local Head of Business Development and establishing integration and reseller agreements, shares fell because investors hate it when companies miss timelines.
With a patent lasting until 2038 and existing interest from potential distribution partners, PainChek anticipates it is well placed. Based on projected US pricing, there is a potential gross annual recurring revenue value of US$85m.
Conclusion
Although the company has a unique technology, whether it realises the ambitions investors have dreamed of realising for so many years, is all up to the FDA. Even though the data for PainChek looks unanimously positive, there is the risk the FDA may decline it on account of other reasons totally at their discretion. Even if it is approved, there is the risk that it may not be accepted by the market. But if the company can obtain FDA approval and PainChek is accepted by the market, the long held dreams of shareholders may finally be achieved.
I look forward to the next day traders pump and dump. Multiple posts on the pump up and silent on the dump down. I will post later how to spot.
